Philip Wong, Ph.D.
ADRC Associate Director
Philip Wong is Professor of Pathology at Johns Hopkins University School of Medicine. His research program is focused on understanding the molecular mechanisms of neurodegenerative disorders, such as Alzheimer's Disease and ALS. With the identification of mutations in genes linked to these diseases, he has taken advantage of transgenic and gene-targeting strategies to reproduce features of the human disorder in mice. He uses these animal models to study disease mechanisms and to design and test therapeutic strategies.
- LaClair KD, Manaye KF, Lee DL, Allard JS, Savonenko AV, Troncoso JC, Wong PC. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. MolNeurodegener.2013; 8: 18-26.
- Li, T, Li Y, Ahn K, Price D, Sisodia S, Wong P. Increased expression of PS1 is sufficient to elevate the level and activity of gamma-secretase in vivo. PLos. One 2011 6: e28179.
- Farrah M, Pan B, Hoffman P, Ferraris D, Tsukamoto T, Nguyen T, Wong PC, Price DL, Slusher B, Griffin JW. Reduced BACE-1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. J Neurosci 2011; 31: 5744-5754.
- Chow V, Savonenko A, Melnikova T, Kim H, Price D, Wong P. Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci Transl Med 2010; 2: 13-17.
- Wong P. Translational control of BACE1 may go awry in Alzheimer's disease. Neuron 2008; 60: 941-943.
Primary Appointment in Pathology